Drug Registration in Iraq: The Complete 2026 Guide

Drug Registration in Iraq: The Complete 2026 Guide for Pharmaceutical Manufacturers

Answer in brief: Drug registration in Iraq is regulated by the Iraqi Ministry of Health (MOH) through the Iraqi Drug Regulatory Authority (IDRA), with public-sector procurement coordinated by the State Company for Marketing Drugs and Medical Appliances (KIMADIA). A foreign pharmaceutical manufacturer typically needs (1) a locally licensed agent or representative, (2) a complete technical dossier in CTD/eCTD format with bilingual Arabic-English labelling, (3) GMP certification from a recognized authority, and (4) successful technical and pricing review. Timelines for a new generic drug typically run 9–18 months from first submission to marketing authorization; innovator pathways and fast-track programs can shorten this for products already approved by reference authorities.

Reviewed by Dr. Rasha Ringa, Founder & General Manager, PKCS. Last reviewed: April 2026.

What is the Iraqi pharmaceutical regulatory framework?

Iraq’s pharmaceutical regulation rests on three institutions that work in coordination but have distinct roles. The Ministry of Health (MOH) sets policy and is the highest authority over all pharmaceutical registration, importation, and post-marketing oversight. The Iraqi Drug Regulatory Authority (IDRA), operating under MOH, is the technical body responsible for dossier review, GMP inspection coordination, pharmacovigilance, and the day-to-day regulatory science of approving medicinal products. The State Company for Marketing Drugs and Medical Appliances (KIMADIA) is a state-owned enterprise that handles centralized public-sector procurement of pharmaceuticals and medical devices for the Iraqi public health system.

For most foreign manufacturers, the practical regulatory journey involves all three: IDRA reviews and grants the marketing authorization, MOH issues the import license, and KIMADIA — for products sold to public hospitals, primary care, and the public supply chain — runs the procurement tenders against which approved products compete. Private-sector commercial sales operate primarily through licensed local distributors and pharmacies, with the MOH/IDRA marketing authorization as the prerequisite.

Who are the regulatory authorities and what do they do?

Iraqi Ministry of Health (MOH)

The MOH is the apex regulatory authority. It promulgates pharmaceutical legislation, issues binding directives on registration and importation, and signs the final marketing authorization certificate. Foreign manufacturers do not typically interact with MOH leadership directly during routine registrations — IDRA is the operational body — but key strategic decisions (national essential medicines lists, accelerated pathways for public health emergencies, import quotas) are made at MOH level.

Iraqi Drug Regulatory Authority (IDRA)

IDRA is the technical regulator. Its responsibilities include reviewing pharmaceutical dossiers for new registrations, approving variations and renewals, coordinating GMP inspections of foreign manufacturing sites, operating the national pharmacovigilance reporting system, and maintaining the registered products database. IDRA’s review is divided into administrative review (completeness check) and technical review (quality, safety, efficacy assessment by therapeutic area committees).

KIMADIA — State Company for Marketing Drugs

KIMADIA is the public-sector procurement arm. After a product is registered with IDRA, KIMADIA is the entity that conducts public tenders to purchase the product for distribution to government hospitals and primary health centers. KIMADIA tender requirements are layered on top of registration — products must be IDRA-registered to participate, and KIMADIA further evaluates pricing, supply reliability, and compliance with Iraqi public-sector specifications. Pharmaceutical companies that target only the private market may interact less with KIMADIA, but most manufacturers find that the public sector is too significant to ignore.

Directorate of Technical Affairs and supporting bodies

Within MOH, the Directorate of Technical Affairs (DTA / DTRA) and various scientific committees support IDRA on specialized assessments — for example, biosimilar evaluation, narcotics and controlled substances scheduling, vaccine evaluation, and medical device classification. Foreign manufacturers in specialty therapeutic areas may need to engage these bodies during registration.

What is the step-by-step Iraq drug registration process?

The standard process for a new pharmaceutical product follows seven phases. Timelines below are directional and assume a complete, high-quality dossier.

  1. Pre-registration strategy and local agent appointment. Before any submission, the manufacturer must appoint a locally licensed agent — typically a pharmaceutical consulting firm or a local representative authorized to act on the manufacturer’s behalf. PKCS provides this local representative service. The agent submits the application, receives correspondence, and represents the manufacturer in front of IDRA.
  2. Pre-submission planning and gap analysis. The agent (or PKCS regulatory affairs team) reviews the existing global dossier against Iraqi requirements, identifies gaps (Arabic labelling, additional stability data, country-specific certificates), and prepares a country-specific submission package. This phase typically takes 4–8 weeks depending on dossier complexity.
  3. Dossier compilation and submission. The technical dossier is assembled in CTD/eCTD format. Iraq accepts the standard ICH CTD structure with country-specific overlays — primarily a Module 1 administrative section adapted to Iraqi requirements (cover letter in Arabic, local agent authorization, fee receipts, GMP certificate, CPP, sample artwork in Arabic).
  4. Administrative review. IDRA’s administrative team checks the dossier for completeness against the formal checklist. Incomplete dossiers are returned without technical review, costing weeks. This is the most common cause of avoidable delay — and the easiest to prevent with experienced submission preparation. Administrative review typically completes in 4–8 weeks.
  5. Technical review. The dossier is assigned to therapeutic area committees that review quality (Module 3), preclinical (Module 4), and clinical (Module 5) data. Reviewers issue deficiency letters listing questions and requests for additional information. Each round of deficiency response and re-review typically takes 6–12 weeks. Most products go through 1–3 deficiency cycles before approval.
  6. Pricing review. Once the technical review is satisfied, the proposed price is reviewed against comparators. Iraq generally references prices in neighboring markets and the country of origin. Pricing approval is its own short cycle, typically 4–8 weeks.
  7. Marketing authorization issuance. The MA certificate is issued, valid for 5 years, after which renewal is required. The product enters the IDRA registered products database and becomes eligible for KIMADIA tenders and private-sector commercialization.

Realistic end-to-end timeline for a generic with a complete, high-quality dossier: 9–18 months. Innovator products with novel dossiers can run longer (18–30 months). Products with reference approvals from EMA, FDA, MHRA, PMDA, or Health Canada often qualify for shorter pathways through reliance mechanisms and reference review acceptance.

What documentation does the Iraq drug dossier require?

Iraq’s dossier requirements broadly follow ICH-CTD structure with country-specific overlays in Module 1. The Module 2–5 scientific content is largely interchangeable with EU/US submissions for products built to those standards.

Module 1 — Administrative and country-specific (Iraq overlay)

  • Cover letter in Arabic and English
  • Application form (IDRA-prescribed format)
  • Power of attorney appointing the local agent (notarized and apostilled or legalized through the Iraqi consulate in the country of origin)
  • Certificate of Pharmaceutical Product (CPP) in WHO format from the country of origin or a reference market
  • Manufacturing license of the producer
  • GMP certificate from a recognized authority (PIC/S inspectorate, EMA, FDA, MHRA, etc.)
  • Marketing authorization in country of origin or reference market
  • Pricing information including ex-factory price, CIF price, and proposed Iraqi retail price
  • Bilingual artwork — primary packaging, secondary packaging, patient information leaflet (PIL), and summary of product characteristics (SmPC) in Arabic and English
  • Samples for laboratory testing
  • Fee receipts

Module 2 — Common Technical Document summaries

Quality Overall Summary (QOS), Nonclinical Overview and Summary, Clinical Overview and Summary. These are essentially identical to EU/US CTD modules and rarely require country-specific work.

Module 3 — Quality (CMC)

Drug substance and drug product chemistry, manufacturing, and controls. Stability data should reflect ICH Climate Zone IVa (hot and humid) or IVb conditions appropriate for Iraq’s climate. Manufacturers using Zone II stability data should plan for additional Zone IV studies.

Module 4 — Nonclinical study reports

For generics with established active pharmaceutical ingredients, Module 4 may be limited or referenced. For new chemical entities and biologics, full nonclinical data is required.

Module 5 — Clinical study reports

For generics, this is primarily bioequivalence study reports against the reference product. For new chemical entities, full clinical development data including pivotal trials. Iraqi reviewers may request post-approval commitments (Phase IV studies in the local population) for novel innovator products.

What does KIMADIA tender consulting involve for foreign manufacturers?

KIMADIA tenders are a parallel commercial pathway alongside private-market sales. Once a product is IDRA-registered, the manufacturer (through its local agent) can register as a vendor in the KIMADIA system and bid on tenders for public-sector supply.

KIMADIA tender practice involves several distinct steps. Vendor registration with KIMADIA verifies the manufacturer and its agent against Iraqi requirements (registration certificate, financial standing, prior performance). Tender announcements are published periodically and define the products being procured, quantities, delivery terms, packaging requirements, and bid evaluation criteria. Bidders submit technical and commercial proposals — the technical proposal proves IDRA registration and product specifications; the commercial proposal is the price and supply terms. Bid evaluation considers price competitiveness, supply reliability, and compliance with the tender specifications. Awards are issued to the winning bidder(s); some tenders split awards across multiple suppliers for supply security.

Common pitfalls for foreign manufacturers in KIMADIA tenders include underestimating the working capital required (KIMADIA payment cycles can be long), under-specifying the local agent’s role in customs clearance and delivery, and quoting prices that do not align with the Iraqi pricing review used during registration. PKCS clients use our regulatory and commercial knowledge to navigate both the registration phase and the tender phase as a single coordinated effort.

What are the most common rejection reasons in Iraqi MOH submissions?

The high-frequency reasons that cause IDRA to return a dossier or issue major deficiencies fall into four categories:

Administrative completeness failures

Missing or incorrectly legalized power of attorney; CPP from a non-recognized country or in non-WHO format; expired GMP certificate; incomplete fee payment; missing local agent declarations. These are the easiest deficiencies to avoid and the most expensive in calendar time when missed.

Bilingual labelling and artwork issues

Arabic translation errors or inconsistencies between the PIL and SmPC; non-compliant packaging artwork (missing batch number positioning, GS1 barcodes, country-of-origin declaration, prescription status indicators); use of brand names that conflict with already-registered products in Iraq.

Stability data gaps

Stability data presented only at ICH Zone II conditions (25°C/60%RH) without Zone IVa or IVb data appropriate for Iraq’s climate. Reviewers increasingly request Zone IVb (30°C/75%RH) for hot-humid storage justification.

Bioequivalence study design issues (generics)

Reference product not approved in a recognized market; bioequivalence study conducted at sites without GCP-accredited bioanalytical labs; inadequate justification for fasted vs fed conditions; statistical analysis not following the EMA bioequivalence guideline.

Variations, renewals, and post-approval lifecycle

A marketing authorization in Iraq is valid for five years and must be renewed before expiry. Renewals require an updated dossier that confirms the registered product is still being manufactured at the approved sites under valid GMP, that pharmacovigilance obligations have been met, that any variations approved during the cycle are reflected in the renewed dossier, and that the product is still considered favorable on benefit-risk.

Variations during the five-year cycle follow categories broadly aligned with EU variation classifications (Type IA, Type IB, Type II, and extensions). Common variations for foreign manufacturers include manufacturing site changes (typically Type II in Iraqi practice), excipient changes, packaging changes, indication extensions, and changes to product information. PKCS coordinates variations to minimize the regulatory load — for example, bundling related changes into a single submission rather than serial filings.

Pharmacovigilance during the post-approval phase is a mandatory ongoing obligation. The marketing authorization holder must report serious adverse drug reactions occurring in Iraq to the MOH/IDRA pharmacovigilance unit within the regulatory deadlines, submit periodic safety reports, and participate in any post-marketing safety initiatives the regulator requires. PKCS pharmacovigilance services include the QPPV function for Iraq and full PV system implementation.

What are the Arabic labelling and bilingual requirements?

Iraqi MOH requires that all primary packaging, secondary packaging, and patient information leaflets be available in both Arabic and English. The Arabic must be a faithful, regulatory-grade translation of the English source — translation errors are a frequent cause of artwork rejection. PKCS produces Arabic regulatory documentation in-house to avoid the typical errors in commercial translation: using the wrong term for a therapeutic area, mistranslating dosing instructions, or inconsistencies between the SmPC and the PIL.

Country-of-origin declarations must be visible on all packaging. Batch number, manufacturing date, and expiry date must follow the Iraqi convention (Western dates are accepted; Hijri calendar is not required but may be added). Prescription status must be clearly indicated. GS1 barcodes are increasingly expected, especially for products entering the public-sector supply chain. KIMADIA tenders for public-sector supply may have additional packaging specifications.

Recent regulatory changes and the 2026 outlook

The Iraqi pharmaceutical regulatory environment continues to evolve toward greater alignment with regional and international standards. Recent themes that PKCS clients are tracking in 2026 include:

  • Continued harmonization with GCC standards — Iraq monitors GCC Health Council decisions and increasingly references the GCC harmonized dossier and central registration outputs.
  • Strengthened pharmacovigilance enforcement — The MOH/IDRA pharmacovigilance unit is increasingly active, with stricter expectations on the timeliness and completeness of adverse event reporting.
  • Bioequivalence study site recognition — IDRA has been progressively narrowing the list of accepted bioequivalence study sites, favoring those with PIC/S, EMA, or FDA recognition.
  • Public-sector pricing pressure — KIMADIA tenders are increasingly competitive on price, reflecting fiscal pressure on the public health budget. Manufacturers should plan their Iraqi pricing strategy with both private and public channels in mind.
  • Digitalization — IDRA continues to develop electronic submission and tracking systems. Manufacturers should plan for an eventual transition to fully electronic dossier submission.

How does PKCS support Iraq drug registration?

PKCS is a Dubai-registered regulatory consulting firm with deep specialization in the Iraqi market. Founder Dr. Rasha Ringa leads engagements that range from one-time registration projects to long-term lifecycle management for portfolios of products. Typical PKCS engagements for Iraq drug registration include:

  • Regulatory affairs — full dossier preparation and submission to IDRA, deficiency response management, marketing authorization through to issuance.
  • Local representative services — PKCS as the registered local agent of record for foreign manufacturers without a presence in Iraq.
  • KIMADIA tender consulting — vendor registration, tender bid preparation, post-award supply coordination.
  • Pharmacovigilance — Iraq-specific PV system implementation and adverse event reporting.
  • GMP support — preparation of the manufacturing site for IDRA-coordinated GMP inspection.
  • Clinical trial application support — for sponsors developing products for or in Iraq.

Most engagements start with a regulatory strategy gap assessment that maps the manufacturer’s existing dossier against Iraqi requirements and gives a realistic, country-specific timeline and resource plan.

Frequently asked questions

How long does drug registration in Iraq take?

For a generic drug with a complete, high-quality dossier and a competent local agent, 9–18 months from first submission to marketing authorization is realistic. Innovator products with novel dossiers can run 18–30 months. Products with prior approval from reference authorities (EMA, FDA, MHRA, etc.) often qualify for accelerated review pathways.

What are the typical fees for Iraq drug registration?

IDRA registration fees are modest by international standards. The larger costs for foreign manufacturers are dossier preparation (Arabic labelling, country-specific overlays, gap-fill studies if needed) and the local agent’s professional fees. PKCS provides transparent, fixed-fee proposals after the initial gap assessment.

Do I need a local Iraqi entity to register a drug in Iraq?

No, foreign manufacturers do not need their own Iraqi entity. They do need a locally licensed agent — typically a pharmaceutical consulting firm or local distributor — authorized to act on their behalf in front of MOH/IDRA. PKCS serves as the local agent for foreign manufacturers under local representative services.

Is Iraq drug registration the same for innovator and generic products?

The administrative process is the same, but the technical content of the dossier differs. Innovator products require full Module 4 nonclinical and Module 5 clinical data. Generics require bioequivalence study reports against an acceptable reference product, plus full Module 3 quality data. Biosimilars follow a separate, more demanding pathway.

What is the difference between IDRA registration and KIMADIA tender approval?

IDRA registration grants the legal right to market the product in Iraq. KIMADIA tender approval is a commercial procurement process — it determines whether a registered product is purchased by the public-sector health system. A product can be IDRA-registered and sold privately without KIMADIA, but cannot win a KIMADIA tender without first being IDRA-registered.

Does Iraq accept the GCC harmonized dossier?

Iraq is not a member of the GCC and does not formally participate in GCC central registration. However, IDRA reviewers are familiar with the GCC harmonized dossier format and content, and a manufacturer with a GCC-ready dossier can adapt it to Iraqi Module 1 requirements with relatively little additional effort.

Can I register a drug in Iraq if it is not yet approved in any reference market?

Yes, but the technical review will be more intensive. Iraq has its own scientific committees that can assess novel products. In practice, foreign manufacturers most often register products that already have a reference approval from a recognized authority — this typically results in a smoother review.

What stability data does Iraq require?

IDRA generally expects ICH Zone IVa (30°C/65%RH) stability data, and increasingly Zone IVb (30°C/75%RH) for products to be stored without specific climate controls. Manufacturers building a global dossier on Zone II conditions only should plan to add Zone IV studies for Iraq submission.

How do I handle a deficiency letter from IDRA?

Deficiency letters are normal and expected. The response strategy is to address every point completely, in writing, with supporting evidence and references to the source dossier sections. PKCS manages deficiency response cycles for clients, maintaining the integrity of the dossier across multiple rounds.

What pharmacovigilance obligations apply once my product is registered?

The marketing authorization holder must maintain a pharmacovigilance system, report serious adverse drug reactions occurring in Iraq within the regulatory deadlines, submit periodic safety reports, and participate in MOH/IDRA-led post-marketing safety initiatives. PKCS provides full pharmacovigilance services for Iraq, including the QPPV function.

Talk to PKCS about Iraq drug registration

PKCS works with pharmaceutical, biotechnology, and medical device companies registering products in Iraq for the first time, expanding existing portfolios, navigating KIMADIA tenders, or managing post-approval lifecycle. Get in touch for a confidential discussion of your Iraq regulatory strategy. Most engagements begin with a gap assessment that gives you a realistic, country-specific plan within two weeks.

Related resources